Clinical and Prognostic Value of Anti-thyrotropin Antibodies in Children with Graves’ Disease

Cover Page

Abstract


The aim of the study was to determine the clinical meaning of TSH receptor antibody (TRAb) measurement in patients with Graves’ disease (GD). We measured the level of total TRAb using the 1 st generation of enzyme multiplied immunoassay and studied thyroid status in 30 children with GD at the onset of disease, every 6 months on antithyroid drug therapy and during 12 months after its discontinuation. We investigated the correlation between the changes of thyroid hormones, thyroid volume and TRAb, so as TRAb level and risk of relapse. Results. At disease onset 87% of children presented with “positive” TRAb values, 13% were considered “ambiguous”. TRAb level normalization was evident in 56% patients in mean 13 ± 5 months of therapy, but 23% demonstrated its elevation in future, mean 1.8 ± 0.2 IU/L. TRAb level and thyroid volume (r s = 0.5, p = 0.01), TRAb and FT4 levels (r s = 0.5, p=0.01) on therapy positively correlated. After discontinuation of medication in 38.9% of patients thyrotoxicosis relapsed (all patients with TRAb > 10 IU/L, 37.5% ofpatients with TRAb 1-10 IU/L, and 14.3% with “negative” values). At the onset of disease Ме TRAb was 12.0 (1.42-38.9) IU/L in relapse group and 6.6 (1.43-25.7) IU/L (р > 0.05) in remission group; at the end of the treatment it became 3.85 (0.64-68.9) IU/L and 0.63 (0.12-6.4) IU/L (р = 0.025) respectively. After therapy discontinuation the relapse group trended to TRAb elevation compared to remission group. “Support” methimazole dose was 0.06 ± 0.04 mg/kg/day in remission group and 0.16 ± 0.04 mg/kg/day (р = 0.003) in relapse group. Conclusion. Measurement of TRAb in children with GD is very useful for prediction of disease progression and therapy results. High TRAb level at the onset of disease and at the end of therapy, absence of normalization on therapy are the risk factors for relapse after therapy discontinuation.

About the authors

References

  1. раверман Л.И. Болезни щитовидной железы. М., 2001.
  2. Бузиашвили И.И., Фадеев В.В., Мельниченко Г.А. Лечение токсического зоба // Врач. 2005. № 23. С. 32-35.
  3. Гланц С. Медикобиологическая статистика. М.: Практика, 1999.
  4. Петунина Н.А. Прогностические факторы и оптимизация методов лечения диффузного токсического зоба: Дис.... докт. мед. наук. М., 2005.
  5. Свириденко Н.Ю., Крюкова И.В., Кеда Ю.М. и др. Клиническое значение иммунологических маркеров диффузного токсического зоба // Проблемы эндокринологии. 1998. № 1. С. 21-24.
  6. Фадеев В.В., Бузиашвили И.И., Абрамова Н.А., Мельниченко Г.А Отдаленные результаты консервативного и хирургического лечения токсического зоба // Проблемы эндокриноло гии. 2004. № 6. С. 3-9.
  7. Adams D., Purves H. Abnormal responses in the assay of thyrotropins. Ргос. Umv. Otаgо. SA. Меё., 1956. P. 34-12.
  8. Braveman L., Utiger R.D. et аl. The thyroid: fundamental and clinical text. Philadelphia. 2000. P. 415.
  9. Brunn J., Block U., Ruf G. et al. Volumetrie der schilddri.isenlappen mittels real-time sonographie // Dtsch. Med. Wochenschr. 1981. V. 106. P. 1338-1340.
  10. Chiovato L., Vitti P., Bendinelli G. et al. Detection of antibodies blocking thyrotropin effect using Chinese hamster ovary ceHs transfected with the cloned hyman TSH receptor // J. Endjcr. Invest. 1994. V. 17. P. 809-816.
  11. Davies T.P., Roti E., Braverman L.E. et al. Thyroid controversy-stimulating antibodies // J. Clin. Endocrinol. Metab. 1998. V. 83. P. 3777-3785.
  12. Dotsch J., Rascher W., Dorr H. Graves disease in childhood: a review of the options for diagnosis and treatment // Pediatr. Drugs. 2003. V. 5. P. 95-102.
  13. Endo K., Kasagi K., Konishi J. et al. Detection and properties of TSH-binding inhibitor immunnoglobulins in patients with Graves’ disease and Hashimoto’s thyroiditis // Clin. Endocrinol. Metab. 1978. V. 46. P. 734-739.
  14. Foley T.P., White C., New B.A. Juvenile Graves disease: usefulness and limitations of thyrotropin receptor antibody determinations // J. Pediatr. 1987. V. 110. P. 378-386.
  15. Glaser N.S., Styne D.M. Predictors of early remission of hyperthyroidism in children // J. Clin. Endocrinol. Metab. 1997. N 82. P. 1719-26.
  16. Gupta M.K. Thyrotropin receptor antibodies: advances and importance of detection techniques in thyroid diseases // J. Clin. Biochem. 1992. V. 25. P. 193-199.
  17. Hamburger J.I. Management of hyperthyroidism in children and adolescents // J. Clin. Endocrinol. Metab. 1985. V. 60. P. 1019-24.
  18. Kashiwai T., Hidaka Y., Takano T. et al. Practical treatment with minimum maintenance dose of anti-thyroid drugs for prediction of remission in Graves’ disease // Endocrine J. 2003. V. 50. P. 45-49.
  19. Kraiem Z., Cho B., Sadeh O. et al. The IgG subclass distributions of TSH receptor bloking antibodies in primary hypothyroidism // J. Clin. Endocrinology. 1992. V. 37. P. 135-140.
  20. Lavard L, Ranlov R., Perrild H. et al. Incidence of juvenile thyrotoxicosis in Denmark, 1982-1988. A nationwide study // Eur. J. Endocrinol. 1994. V. 130. P. 565-568.
  21. Lucas A., Salinas I., Rius F. et al. Medical therapy of Graves’ disease: does thyroxine prevent recurence of hyperthyroidism? // J. Clin. Endocrinol. Metab. 1997. V. 82. P. 2410-2413.
  22. Matsuura N., Yamada Y., Nohara Y. et al. Familial neonatal transient hypothyroidism due to maternal TSH-binding inhibitor immunnoglobulins // N. Engl. J. Med. 1980. V. 303. P. 738-41.
  23. Michelangeli V.P., Munro D.S., Poon C.W. et al. Measurement of thyroid stimulating immunoglobulins in a new cell-lines transfected with a functional human TSH receptor (Jpa9 cells), compared with an assay using FRTL-5 cells // J. Clin. Endocrinol. 1994. V. 40. P. 645-652.
  24. Morgenthaler N.G., Pampel I., Aust 0. et al. Application of a bioassay with cells for the routine detection of stimulating and blocking autoantibodies to the TSH-receptor // Horm. Metab. Res. 1998. V. 30. P. 162-168.
  25. Mussa G., Corrias A., Silvestro L. et al. Factors at onset predictive of lasting remission in pediatric patients with Graves’ disease followed for at least three years // J. Pediatr. Endocrinol. Metabol. 1999. V. 12. P. 537-541.
  26. Nagayama Y., Wadsworth H.L., Russo D. et al. Binding domains of stimulatory and inhibitory thyrotropin (TSH) receptor autoantibodies determined with chimeric TSH-lutropin/chorionic gonadotropin receptors // J. Clin. Invest. 1991. V. 88. P. 336-340.
  27. Orgiazzi J. Anti-TSH receptor antibodies in clinical practice // J. Endocrinol. Metab. Clin. North. Am. 2000. N 229. P. 339-355.
  28. Pastan I., Roth J., Macchia V.Binding of hormone to tissue: the first step in polypeptide hormone action // Proc. Natl. Acad. Sci. USA. 1966. V. 56. P. 1802-1809.
  29. Rapoport B., Greenspan F.S., Filetti S. et al. Clinical experience with a human thyroid cell bioassay for thyroid-stimulating immunoglobulin // J. Clin. Endocrinol. Metab. 1984. V. 58. P. 332-338.
  30. Rees Smith B., McLachlan S.M., Furmaniak J. Autoantibodies to the thyrotropin receptor // Endocr. Rev. 1988. V. 9. P. 106-121.
  31. Rittmaster R.S., Zwicker H, Abbott E.C. et al. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves’ disease // J. Clin. Endocrinol. Metab. 1996. V. 181. P. 3283-3288.
  32. Roti E., Davies T.F., Braveerman E., DeGroot J. Thyroid controversy: stimulating antibodies // J. Clin. Endocrinol. Metab. 1998. V. 83. P. 3777-3785.
  33. Schott M., Morgenthaler N.G., Fritzen R. et al. Levels of autoantibodies against human TSH receptor predict relaps of hyperthyroidism in Graves’ disease // Horm. Metab. Res. 2004. V. 36. P. 92-96.
  34. Shibayama K., Ohyama Y., Yokota Y. et al. Assays for thyroid-stimulating antibodies and thyrotropin-binding inhibitory immunnoglobulins in children with Graves’ disease // Endocrine J. 2005. V. 52. P. 505-510.
  35. Smith B.R., HaH R. Binding of thyroid stimulators to thyroid membranes // FEBS Lett. 1974. V. 42. P. 301-304.
  36. Takasu N., Oshiro C., Akamine H. et al. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves’ patients and in 686 normal subjects // Endocrinol. Invest. 1997. V. 20. P. 452-461.
  37. Takasu N., Yamashiro K. et al. Remission of Graves’ hyperthyroidism predicted by smooth decreases of thyroid-stimulating antibody and thyrotropin-binding inhibitor immunoglobulin during antithyroid drug treatment // Thyroid. 2000. V. 10. P. 891-986.
  38. Vitti P., Velente V., Ambesi-Impiombato F.S. et al. Graves’ IgG stimulation of continuously cultured rat thyroid cells: a sensitive and potentially useful clinical assay // J. Endocrin. Invest. 1982. V. 5. P. 179-182.
  39. Volpe R. Thyroid function and disease. In.: Burrow G.N. et al. (Ed.). Philadelphia., 1989. P. 191-207.
  40. Weetman A.P., Yateman M.E., Ealey P.A. et al. Thyroid-stimulating antibody activity between different immunoglobu1in G subc1asses // J. Clin. Invest. 1990. V. 86. P. 723-727.
  41. World Health Organization. United Nations Children’s Fund. ICCIDD. Assessment of iodine deficiency disorders and monitoring their elimination. A guide for program managers. Geneva: WHO, 2001.
  42. Zimmermann-Belsing T., Nygaard B., Rasmussen A.K. et al. Use of the 2-nd generation TRAK human assay did not improve prediction of relapse after antithyroid medical therapy of Graves’ disease // Eur. J. Endocrinology. 2002. V. 146. P. 173-177.

Statistics

Views

Abstract - 505

PDF (Russian) - 419

Cited-By


PlumX

Dimensions


Copyright (c) 2006 ., ., ., ., .

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies